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Treatment efﬁciencyThe notion of a limited, early period of plasticity of the visual system has been challenged by more recent
research demonstrating functional enhancement even into adulthood. In amblyopia (‘‘lazy eye’’) it is still
unclear to what extent the reduced effect of treatment after early childhood is due to declining plasticity
or lower compliance with prescribed patching. The aim of this study was to determine the dose–response
relationship and treatment efﬁciency from acuity gain and electronically recorded patching dose rates,
and to infer from these parameters on a facet of age dependence of functional plasticity related to occlu-
sion for amblyopia. The Occlusion Dose Monitor was used to record occlusion in 27 participants with pre-
viously untreated strabismic and/or anisometropic amblyopia aged between 5.4 and 15.8 (mean 9.2)
years during 4 months of conventional treatment. Group data showed improvement of acuity throughout
the age span, but signiﬁcantly more in patients younger than 7 years despite comparable patching dos-
ages. Treatment efﬁciency declined with age, with the most pronounced effects before the age of 7 years.
Thus, electronic recording allowed this ﬁrst quantitative insight into occlusion treatment spanning the
age range from within to beyond the conventional age for patching. Though demonstrating improvement
in over 7 year old patients, it conﬁrmed the importance of early detection and treatment of amblyopia.
Treatment efﬁciency is presented as a tool extending insight into age-dependent functional plasticity
of the visual system, and providing a basis for comparisons of effects of patching vs. emerging alternative
treatment approaches for amblyopia.
 2014 Elsevier Ltd. All rights reserved.1. Introduction
Amblyopia is a, usually unilateral, impairment of visual func-
tions originating from abnormal visual experience during develop-
ment. Being induced by strabismus (squint), anisometropia
(unequal refractive power of the two eyes) or visual deprivation,
it is a frequent cause of visual loss in childhood (Attebo et al.,
1998). Occlusion (patching) of the nonamblyopic eye is still the
mainstay of treatment (Loudon & Simonsz, 2005; Wong, 2012).Amblyopia and its treatment have served as natural model sit-
uations for studying the susceptibility of the visual system to
altered visual input (for reviews see e.g. Daw, 1998; Sireteanu,
2000). Both clinical experience with treatment and extrapolations
from animal models (e.g. Hubel & Wiesel, 1970) led to the notion
that successful amblyopia treatment is conﬁned to the ﬁrst 6–
8 years of life (Von Noorden & Crawford, 1979). More recently,
the concept of a rigid adult visual system lacking plasticity has
been challenged (e.g. reviews by Gilbert, 1998; Levi, 2005;
Spolidoro et al., 2009). A large number of (sometimes quite contro-
versial) psychophysical, neurophysiological and clinical studies
suggested varying degrees of susceptibility to change beyond
school entry age (Daw, 1998; Epelbaum et al., 1993; Scheiman
et al., 2005; Wandell & Smirnakis, 2009).
Amblyopia treatment lacks standardization concerning not only
dosage, but also age limits. This is reﬂected in textbooks with age
limits between ‘‘about 8’’ (Von Noorden & Campos, 2002) and
12 years (Haase & Graef, 2004) and in clinical guidelines
(American Academy of Ophthalmology: until 2007 ‘‘10 years’’,
Table 1
Baseline characteristics of the patients.
Patient
no.
Age
(years)
Eye Refraction [D] Angle of squint (near)
[PD]
Initial acuity crowded Landolt
[logMAR]
History
1 5.4 RE⁄ +8.0 2.0/170 ±0 0.8 Untreated
LE +4.75 0.75/0 0.2
2 5.6 RE⁄ +8.0 0.5/0 +10 1.3 Untreated
LE +7.75 0.25/
44
0.5
3 5.7 RE⁄ +2.0 +14 1.7 Untreated
LE +2.25 0.2
4 6.0 RE⁄ +3.0 ±0 0.3 Untreated
LE +1.0 0.1
5 6.0 RE +0.75 ±0 0.0 Untreated
LE⁄ +6.5 0.5/160 1.0
6 6.0 RE +5.5 +2 0.1 Untreated
LE⁄ +5.25 0.5/0 1.0
7 6.6 RE⁄ +2.25 +16 0.8 Untreated
LE +2.75 0.2
8 6.9 RE +2.25 0.5/
140
+6 0.1 Untreated
LE⁄ +4.75 1.0/20 1.0
9 7.1 RE⁄ 1.25 +1.25/
100
±0 0.3 Untreated
LE 0.25 0.1
10 7.2 RE +1.5 ±0 0.1 Untreated
LE⁄ +5.25 0.75/
156
0.7
11 7.2 RE 0.0 VD 2 0.1 Untreated
LE⁄ +1.25 0.75/
155
0.3
12 7.3 RE⁄ +6.0 2.0/170 Micro 1.0 Untreated
LE +5.75 2.0/
180
0.1
13 7.7 RE⁄ +5.5 1.5/100 Micro 1.0 Untreated
LE 0.0 0.1
14 8.9 RE⁄ +3.5 3.75/
175
±0 0.6 Untreated
LE +0.5 0.1
15 9.0 RE +0.75 0.75/0 +8 0.1 Untreated (occlusion prescribed at 4–5 yrs., not
done)
LE⁄ +6.75 1.1
16 9.1 RE +2.5 ±0 0.1 Untreated
LE⁄ +7.0 3.5/0 0.4
17 10.4 RE⁄ +3.25 0.75/
160
+35 1.1 Untreated
LE +3.25 0.3
18 10.6 RE⁄ +2.0 4.5/175 ±0 0.2 Untreated
LE 0.0 0.25/5 0.1
19 11.4 RE +1.0 1.0/10 ±0 0.1 Untreated
LE⁄ +6.0 0.5/175 0.8
20 11.6 RE 0.0 ±0 0.1 Untreated
LE⁄ +2.0 1.5/180 0.3
21 11.7 RE +0.5 0.5/5 ±0 0.1 Untreated (occlusion prescribed earlier, not
done)
LE⁄ +1.25 3.0/0 0.1
22 12.1 RE 0.75 0.25/
62
Micro 0.1 Untreated
LE⁄ 0.0 0.8
23 12.4 RE⁄ +4.5 2.5/10 Micro 0.9 Untreated (occlusion prescribed at 7 yrs., not
done)
LE +4.0 2.5/0 0.0
24 13.1 RE⁄ +2.75 0.25/
30
+6 0.8 Untreated (1 month occlusion at 4–5 yrs. ‘‘tried’’)
LE +1.5 0.25/0 0.1
25 13.6 RE⁄ +3.0 1.75/
165
+10 0.6 Untreated (occlusion prescribed earlier, not
done)
LE 0.0 0.75/5 0.0
26 14.3 RE 0.5 0.5/171 ±0 0.0 Untreated
LE⁄ 1.5 2.25/6 0.3
27 15.8 RE +1.5 0.5/60 +18 0.1 Untreated
LE⁄ +3.75 0.5/25 1.7
Means: 9.2 Means NAE: 0.04
SD: 3.1 SD NAE: 0.15
Means AE: 0.77
SD AE: 0.42
D = diopter, PD = prism diopter. The asterisk marks the amblyopic eye. RE = right eye; LE = left eye; VD = vertical deviation, NAE = nonamblyopic eye; AE = amblyopic eye;
SD = standard deviation.
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M. Fronius et al. / Vision Research 103 (2014) 11–19 13more recently changed to ‘‘all children . . .. regardless of age’’;
German Ophthalmological Society guideline, 2010: ‘‘up to
18 years’’). Clinical practice varies accordingly: a questionnaire
answered by German and Dutch ophthalmologists and orthoptists
yielded upper age limits for the prescription of patching between 4
and 60 years (Fronius et al., 2007), with 20% of the ophthalmolo-
gists choosing never to prescribe occlusion treatment beyond the
age of 7 years. It is still unclear to what extent less successful treat-
ment in older children and adolescents is due to lower compliance
with prescribed treatment or actually to reduced plasticity.
The electronic Occlusion Dose Monitor (ODM) allowed objective
monitoring of occlusion treatment (Fielder et al., 1994; Simonsz
et al., 1999) as well as the calculation of dose–response relation-
ship, so far mainly in patients of the conventional treatment age
between 3 and 8 years (Monitored Occlusion Treatment of Ambly-
opia Study MOTAS – Stewart et al., 2004b, 2007a; Randomized
Occlusion Treatment for Amblyopia Study ROTAS – Stewart et al.,
2007b). We demonstrated in a pilot study, including patients with
or without previous treatment, that it was feasible to apply occlu-
sion with electronic monitoring between the age of 7 and 16 years
(Fronius, Bachert, & Lüchtenberg, 2009). Here we assessed more
patients of an extended age range (between 5 and 16 years), all
previously untreated, using uniform function tests in the whole
group. The aim was to extend knowledge beyond the age investi-
gated by ROTAS and MOTAS into a less studied age range where
susceptibility to treatment and thus plasticity is presumably lower
(Epelbaum et al., 1993).
We introduced a calculation of treatment efﬁciency as a mea-
sure of a speciﬁc aspect of functional plasticity in the human visual
system related to amblyopia and patching.2. Methods
2.1. Participant inclusion and assessment
Participants with strabismic and/or anisometropic amblyopia,
between 5 and 16 years of age were included if they were able to
accomplish acuity testing with single and crowded Landolt rings.
A log minimum angle of resolution (logMAR) acuity difference
between the eyes of at least 0.2 after a period of refractive adapta-
tion (wearing glasses for at least 6 weeks before commencing
patching, see e.g. Stewart et al., 2004a) was required for inclusion.
Patients were not included if they had: other eye disorders;Fig. 1. Relationship between patient age at initiation of occlusion treatment and acuity
model for these data, therefore no regression line is shown.deprivation amblyopia; diminished acuity due to medication, brain
damage, or trauma; neurological disorders; spontaneous or easily
inducible diplopia; or if the journey to the patient’s home was
too long for regular visits by researchers for the exchange of the
ODM. All patients had a full ophthalmic assessment (including
cycloplegic retinoscopy and funduscopy) as well as orthoptic
assessment (including angle of strabismus, binocular vision, pat-
tern of ﬁxation determined with the visuscope) before study entry
(for details see Fronius, Bachert, & Lüchtenberg, 2009). Prescribed
occlusion was usually 6 h/day, unless the treating orthoptists had
reasons to deviate from this practice. Visual acuity, scored by line
(criterion 4/6 correct), was assessed every 3–5 weeks. Crowded
Landolt ring charts with optotype separation 2.6 minarc (Oculus,
Wetzlar, Germany) presented at 40 cm distance were used for all
patients. Occlusion was recorded using more recent versions of
the ODM developed in the Netherlands (Simonsz et al., 1999),
which were tested and applied for continuous recording in several
previous studies (Awan, Proudlock, & Gottlob, 2005; Chopovska
et al., 2005; Fronius, Bachert, & Lüchtenberg, 2009; Fronius et al.,
2006; Kracht et al., 2010). Being taped to the occlusion patch, they
measure the temperature difference between the patch on the eye
and the surroundings. The families also wrote diaries of daily
occlusion, so that occlusion times could be completed from the dia-
ries in occasional cases of ODM failure (Fronius, Bachert, &
Lüchtenberg, 2009).
The research adhered to ‘‘the Code of Ethics of the World Med-
ical Association (Declaration of Helsinki)’’. The Ethics Committee of
the University of Frankfurt approved the study protocol prior to
initiation of the study. Written informed consent was obtained
from all parents and from participants older than 14 years, and
all participants gave assent, prior to inclusion in the study.2.2. Study participants
Thirty-ﬁve patients aged between 5.4 and 15.8 years were
recruited from the outpatient clinic of the Pediatric Ophthalmology
Department of the University of Frankfurt and several ophthalmol-
ogists’ ofﬁces. Two were not included (one because of comprehen-
sion problems, the other because of lack of time of the family). One
patient dropped out right after study onset because of parental ill-
ness, one lost the ODM immediately and refused to continue par-
ticipation. Thus, data of 31 patients were recorded. Only
previously untreated patients (n = 27; mean age 9.2 years ± 3.1)gains (log units) after 4 months of patching. Linear regression was not an adequate
Table 2
Electronically recorded occlusion (mean dose rate in h/d ± SD) during the 1st, during the 2nd to 4th months and during the whole 4 months period of treatment.
Group (n; mean age ± SD) 1st month 2nd to 4th months 0–4 months
All (n = 27; 9.2 ± 3.1) 4.46 ± 1.43 4.07 ± 1.85 4.19 ± 1.63
Age <7 years (n = 8; 6.0 ± 0.5) 4.00 ± 1.97 3.47 ± 1.69 3.56 ± 1.68
Age 7–11 years (n = 10; 8.4 ± 1.3) 4.46 ± 1.30 4.66 ± 1.73 4.64 ± 1.63
Age >11 years (n = 9; 12.9 ± 1.4) 4.88 ± 0.96 3.94 ± 2.10 4.25 ± 1.59
Table 3
Overview of age dependence of dose–response relationship, combined from math-
ematical modeling data of Stewart et al. (2007a) and our data. In accordance with
Stewart et al., the table presents hours of occlusion needed to gain 2 logMAR lines (0.2
log units).
Source of data Age Hours occlusion for 2 lines gain
(h)
Stewart et al.
(2007a)
4 years 170
6 years 236
Fronius et al. Mean age 6.0 years 220
Mean age 8.4 years 490
Mean age
12.9 years
426
Table 4
Efﬁciency data (medians, ranges) for the whole sample as well as for the three age
groups after 1 and after 4 months of treatment, and results of statistical comparisons
(Kruskal–Wallis tests) between groups. Unit for all is log units acuity gain per 100 h
occlusion.
Group After 1 month After 4 months
All 0.125 0.05
(0.08 to 0.92) (0–0.39)
Age <7 years 0.19 0.11
(0–0.92) (0.04–0.39)
Age 7–11 years 0.13 0.05
(0–0.375) (0.02–0.10)
Age >11 years 0.07 0.04
(0.08 to 0.24) (0–0.12)
Stat.:
<7 years vs. 7–11 years p = 0.422 p = 0.051
<7 years vs. >11 years p = 0.094 p = 0.014
7–11 years vs. >11 years p = 0.422 p = 0.400
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istics at the baseline assessment are shown in Table 1. The data of 7
participants, all older than 7 years (nrs. 10, 11, 15, 19 and 25–27),
have also been analyzed in our previous pilot study (Fronius,
Bachert, & Lüchtenberg, 2009), in which the limited number of par-
ticipants did not allow the analysis of age dependence of treatment
effects, nor did it include patients younger than 7 years or treat-
ment efﬁciency calculation. The age range overlapping with that
of ROTAS/MOTAS was to allow testing for comparability of the
procedures.
With logMAR acuities of the amblyopic eyes between 1.7 and 0.1
(interocular differences 1.8–0.2) the group comprised the whole
spectrum from severe to mild amblyopia. Eight patients had stra-
bismic amblyopia, 12 anisometropic and 7 combined etiology.
2.3. Data analysis, statistics
To calculate dose–response relationship and treatment efﬁ-
ciency as measures of plasticity, both occlusion recorded by means
of the ODM and crowded Landolt ring acuity gains were evaluated
after 1 and 4 months of treatment. Some of these data were also
analyzed in the context of methodological studies assessing the
practicability of continuous electronic recording of occlusion in
patients of various ages (Chopovska et al., 2005; Fronius, Bachert,
& Lüchtenberg, 2009; Fronius et al., 2006; Kracht et al., 2010).
The periods of 1 and 4 months were chosen for the present analysis
in order to include the rapid initial changes as well as the time
span during which most of the improvement occurs according to
previous reports (Kracht et al., 2010; Pediatric Eye Disease
Investigator Group, 2003; Stewart et al., 2007b). This is a period
during which hardly any changes in prescription are necessary,
and during which the majority of the patients may be followed
without too many drop-outs. According to ROTAS (Stewart et al.,
2007b), the maximal time to reach best acuity was 89 days in chil-
dren up to 8 years of age. We chose 4 months to allow for possibly
more protracted improvement in our older patients.
Treatment efﬁciency was calculated as: acuity gain [log
units] * 100/recorded occlusion [h] in the same period. Efﬁciency val-
ues convey the acuity gain per 100 h of administered occlusion
during a certain period of treatment.
The following statistical procedures were applied, based on the
nature of the data: one-way repeated measures ANOVA by ranks
(Friedman test with multiple comparisons by Conover) forcomparison of data between study entry, and 1 and 4 months of
occlusion; Wilcoxon matched-pairs test (WMP) for analysis of
changes in occlusion dose rate between the two treatment inter-
vals (1st month vs. 2nd to 4th months); one-way ANOVA with
multiple Scheffé comparisons, Kruskal–Wallis one-way analysis
of variance with multiple Conover–Iman comparisons or Wilco-
xon–Mann–Whitney Test (WMW) to compare different groups of
patients. Simple regression analysis or Spearman’s rank correlation
using Edgeworth approximation was applied to study relationships
among variables. Multiple regression with backward elimination
was used to analyse inﬂuencing factors for treatment efﬁciency.
P-values < 0.05 were considered statistically signiﬁcant. All tests
were performed using the statistics software package BiAS
10.04 1989–2013 epsilon-publishing.3. Results
3.1. Acuity gain
Mean initial, pre-patching acuity of the amblyopic eyes of all
patients was 0.77 logMAR ± 0.42, and of the nonamblyopic eyes
0.04 ± 0.15 (see Table 1 for individual values). There was no signif-
icant correlation between patient age and initial logMAR values of
the amblyopic eyes (r = 0.12; p = 0.54). LogMAR values improved
signiﬁcantly after 1 month as well as after 4 months of treatment
compared to the initial acuity, and also between the 1 and
4 months assessments (all: p < 0.001 Friedman test), indicating
that the treatment was effective for the patient group during the
period analyzed. After 1 month of treatment, all but 7 patients
(one 6 years old, the others older than 9 years) showed improved
acuity, with a median gain in the whole sample of 0.1 log unit
(range 0.1 to 0.9). After 4 months, all but 3 (all over 11 years
old) improved at least one line, with a median gain of 0.3 log units
(range 0–1.4).
Fig. 1 shows the individual acuity gains after 4 months of patch-
ing as a function of age. In spite of some overlap, the data show a
tendency toward less improvement with increasing age: zero gain
occurred exclusively in patients older than 11 years, and the
Fig. 2. Relationship between patient age at initiation of treatment and efﬁciency in acuity gain after 4 months of occlusion of 27 previously untreated patients (black squares).
Linear regression between age and logarithmically transformed efﬁciency data was signiﬁcant (r = 0.51; p = 0.007). Crosses and numbers to the left: selected individual
efﬁciency calculated from dose–response data of 3–8 years old patients from the MOTAS study (Stewart et al., 2004b, Fig. 4A; see text 3.3 for details), conﬁrming that
efﬁciency of the magnitude shown by some of our youngest patients (and even much higher, as the numbers are beyond the scale of our ordinate) is not uncommon in this
age range.
M. Fronius et al. / Vision Research 103 (2014) 11–19 15maximum gain was 0.3 log units in that group. All patients younger
than 7 years achieved at least 0.3 log units, and the maximum gain
was 1.4 log units in one of the youngest patients.
A simple linear regression model was not adequate for this data
because of outliers. Spearman’s rank correlation between age and
acuity gain after 4 months was signiﬁcant (rho = 0.58;
p = 0.002). Kruskal–Wallis one-way analysis of variance revealed
signiﬁcant differences between gains of patients younger than
7 years (n = 8; mean age 6.0 ± 0.5; median gain 0.4 log units) and
those between 7 and 11 years (n = 10; mean age 8.4 ± 1.3; median
gain 0.25 log units; p = 0.043) as well as those older than 11 years
(n = 9; mean age 12.9 ± 1.4; median gain 0.2 log units; p = 0.003);
the difference between the two older age groups was not signiﬁ-
cant (p = 0.164). Initial acuities were not signiﬁcantly different
between any of these three age groups (one-way ANOVA all
p > 0.286). All age groups comprised patients with and without
strabismus (<7 years: 37.5% no strabismus, 62.5% strabismus; 7–
11 years: 50% with and without strabismus, respectively;
>11 years: 44.4% no strabismus, 55.6% strabismus).3.2. Electronically recorded occlusion
The question whether the more pronounced acuity gains in the
younger patients were attributable to higher occlusion dose rates
was analyzed based on the ODM recordings. Following average
prescription of 5.44 ± 1.08 h/d, the mean daily received dose rate
in the whole group of patients during 4 months of patching was
4.19 ± 1.63 h/d, with individual values extending between 0.75
and 7.99 h/d. Linear regression revealed no signiﬁcant relationship
between age and occlusion dose rate (r = 0.02; p = 0.908). Table 2
shows all the mean dose rates, of the whole group of patients and
then separately for each of the three previously analyzed age
groups, separated into the ﬁrst month, 2nd to 4th months and
the whole period of 4 months of treatment.
There were no signiﬁcant differences in daily dose rates
between any of the three age groups during the ﬁrst month or dur-
ing the 2nd to 4th month time period (one-way ANOVA, all
p > 0.100). Although mean occlusion changed slightly between
the ﬁrst and the following 3 months, none of the differences werestatistically signiﬁcant (all p > 0.100 WMP). The youngest group
occluded on average even slightly less than the other two groups
(see Table 2). Thus, the signiﬁcantly more pronounced acuity gains
in the younger patients were not caused by higher occlusion dose
rates.3.3. Dose–response relationship and efﬁciency of occlusion therapy
After one month of treatment the median dose–response rela-
tionship was 58.25 h/0.1 log unit acuity gain (range between
124.13 h/0.1 log unit acuity gain in one patient who gained 1 line
in the nonamblyopic and lost one in the amblyopic eye, and
186.90 h/0.1 log unit). The median for 4 months of treatment was
169.19 h/0.1 log unit (range 25.90–539.29 h/0.1 log unit).
Table 3 combines our data with those of MOTAS (Stewart et al.,
2007a), extending the age range over which dose–response rela-
tionship was calculated based on objective recording of occlusion.
To be consistent with the article of Stewart and colleagues, dose–
response relation is presented in the table as hours of occlusion
needed to gain 0.2 log units acuity.
The dose–response relationship becomes more unfavorable
with age (see Table 3). At age 6 years, dose–response speciﬁed both
in our study and MOTAS showed good agreement (220 vs. 236 h/
0.2 log units), conﬁrming the comparability of the data. Patients
who showed no change in visual acuity (6 during the ﬁrst month
and 3 after 4 months) had to be excluded from this dose–response
calculation because of division by zero. Patients excluded from the
4 months calculation were all older than 11 years.
The treatment efﬁciency data (expressed as acuity gain [log
units] per 100 h of patching) are shown in Table 4. Efﬁciency of
the whole group ranged between 0.08 and 0.92 after 1 month
(median 0.125) and 0–0.39 after 4 months (median 0.05). As to
age dependence, after the ﬁrst month of patching median efﬁ-
ciency decreased from 0.19 in the group of patients aged younger
than 7 years to 0.13 in the middle age group and to 0.07 in those
older than 11 years, but these differences were not statistically sig-
niﬁcant at this early stage (see Table 4). After 4 months of treat-
ment, the difference between the youngest (median 0.11) and
the oldest age group (median 0.04) was signiﬁcant (p = 0.014).
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dose–response and 2.4 for efﬁciency.
In a comparison of participants with strabismus (n = 15) to
those without strabismus (n = 12), neither acuity gain nor treat-
ment efﬁciency were signiﬁcantly different (all: p > 0.100,
WMW). Application of multiple regression analysis with backward
elimination on the data of the whole group revealed that of the fac-
tors analyzed (age, recorded dose rate, initial acuity and presence
or absence of strabismus), initial acuity (p = 0.023), age
(p = 0.003) and recorded dose rate (p = 0.001) remained as signiﬁ-
cant independent inﬂuencing factors for treatment efﬁciency after
4 months of patching.
Fig. 2 illustrates the age dependent decline of efﬁciency over the
whole age range of individual patients after 4 months of treatment.
The graph suggests again – despite some overlap – that the age
of 7 years seems to mark a change in the susceptibility of the visual
system to treatment: efﬁciency over 0.123 occurred exclusively in
patients younger than 7 years, efﬁciency of less than 0.04 only in
those over 7. Fig. 2 also includes for comparison, efﬁciency data
calculated from the inverse of the dose–response values of
Stewart et al. (2004b) available in their Fig. 4A in patients between
3 and 8 years (albeit without detailed speciﬁcation of age). The
selected data shown (crosses and numbers to the left side of our
Fig. 2) conﬁrm that efﬁciency of the magnitude found in some of
our youngest patients (and even much higher) is not uncommon
in this age range.
A linear regression model was not adequate for our efﬁciency
data. Logarithmic transformation of the values according to a proce-
dure taking into consideration zero efﬁciency (Berry, 1987) yielded
a signiﬁcant (p = 0.007; r = 0.51) linear regression with age.4. Discussion
4.1. Evaluation of our data
This study provided the ﬁrst quantitative account of the age
dependent decline of occlusion treatment efﬁciency between
about 5 and 16 years, with the maximal effect occurring before
7 years. The application of the ODM technology supplied interest-
ing insights into the susceptibility of the visual system based on
quantiﬁed periods of enforced use of the amblyopic eye in a rare
group of previously untreated amblyopes. Spanning for the ﬁrst
time an age range from within to beyond the conventional age
for patching, this study includes the age range which is within
the focus of current alternative treatment approaches (see Section
4.4). The age range of 5–8 years, overlapping with that of previous
studies (e.g. Stewart et al., 2004b), conﬁrmed comparability with
existing data, rendering the collection of a larger sample of this
age unnecessary (see e.g. Table 3). Moreover, our current ﬁndings
in the mean age group 12.9 years (dose–response 426 h/0.2 log
units gain) are consistent with the dimension of the dose–response
values from our earlier pilot study (Fronius, Bachert, &
Lüchtenberg, 2009) with a small patient sample comprising previ-
ously treated and untreated amblyopes of mean age 11.1 years and
468 h/0.2 log units gain. The availability of objective occlusion data
allowed the calculation of treatment efﬁciency, proposed here as
an index of age dependent susceptibility of the visual system. It
is important to note that patching treatment for amblyopia is a
commonly used (Wong, 2012), albeit speciﬁc approach to investi-
gate visual system plasticity. We detected a source of bias in the
analysis of age dependence of dose–response relationship: patients
whose acuity remains unchanged have to be excluded from the cal-
culation because of division by zero. Calculation of efﬁciency
avoids this problem. As our data shows, this was more likely in
the older amblyopes (only over 11 year old patients after 4 monthsof treatment), and may therefore inﬂuence assumptions about the
magnitude of reduction of plasticity with increasing age. These
ﬁndings are relevant both in a neuroscientiﬁc context and with
regard to further optimization of amblyopia treatment. Signiﬁcant
improvement in visual acuity was found not only in the youngest,
but also in the older groups after 4 months, conﬁrming that it is
worthwhile considering treatment beyond 7 years of age. The sig-
niﬁcantly more pronounced effects in the youngest age group
regarding most ﬁndings emphasize the relevance of early detection
and urgent treatment of amblyopia. It is important to note that
during 4 months of treatment none of the patients reported serious
side effects, but exclusion of patients who tend to experience dip-
lopia without much dissociation of the images of the two eyes is
advisable.
Both data collection and evaluation were very time-consuming.
But the procedure of continuous recording with frequent
exchanges of the ODM during home visits by researchers pre-
vented signiﬁcant drop-out of patients from the study and mini-
mized data loss. Patients older than 7 years (especially previously
untreated ones) rarely show up for treatment, and the number of
available ODMs was limited (Fronius, 2011; Simonsz, 2012). It
was advantageous that the age groups were representative and
comparable as to the etiology and severity of amblyopia, and that
their actual accomplishedmean occlusion was not signiﬁcantly dif-
ferent. We are aware that the patient sample consisted of selected
families accepting the ODM recording, which may inﬂuence com-
pliance with treatment and thus outcome. Yet, despite knowledge
of monitoring, compliance (calculated as recorded/prescribed dose
rate) ranged between 0.17 and 1.65 (mean 0.77) during the period
of four months of treatment. It was not the aim of this research to
collect compliance data representative for the common clinical
population, but to gain insight into dose–response and efﬁciency
as indices for age dependent plasticity. Despite occasional inter-
ruptions due to ODM failure, by combining the recordings with
patients’ diaries (Fronius, Bachert, & Lüchtenberg, 2009), this is
so far the most advanced way of continuous monitoring of treat-
ment over several months. As the families were aware of the
recording, agreement between ODM data and diaries was usually
very good, even if compliance was poor. If agreement was not sat-
isfactory, prompt feedback from the researchers enhanced the
quality of the diaries. And of course, patients and their families
were not aware if and when an ODM failed to record.
In addition to the factors identiﬁed by the multiple regression
model as signiﬁcant for treatment efﬁciency (age, initial acuity,
occlusion dose rates), it cannot be ruled out that some of the var-
iability in the data may be related to different types of activities
that the patients engaged in during patching. All were advised to
do demanding near work at least part of the time. A PEDIG study
(2008) found no signiﬁcant difference in acuity improvement
between near and distance activities during patching.
4.2. Relationship to previous studies
Most previous studies investigating the age dependence of the
effect of occlusion treatment for amblyopia had a clinical back-
ground, and with a few exceptions (Awan, Proudlock, & Gottlob,
2005; Stewart et al., 2004b, 2007a, 2007b), all lacked objective data
of accomplished patching. Epelbaum et al. (1993), in an interesting
analysis of the inﬂuence of age, reported plasticity close to zero
from about 11 years of age. Our four patients aged 12.1–14.3 years
who gained 0.3 log units, as well as data by Mohan, Saroha, and
Sharma (2004), suggest that the conclusion of Epelbaum and col-
leagues may have been mislead by lack of knowledge of their
patients’ compliance. The ‘‘rate of responders’’ (patients achieving
at least 0.2 log units improvement) after 4 months of treatment
was higher in our patients older than 7 years than in the respective
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scribed and actually received dose rates in our study.
A large number of studies agree that there is residual plasticity
in amblyopes beyond the once assumed age of 6 or 8 years and
even into adulthood (Chen, Song, & Wu, 2003), emphasizing either
the importance of age (Fulton & Mayer, 1988; Holmes et al., 2011;
Rutstein & Fuhr, 1992; Sattler, 1927) or of compliance (Arnold,
Armitage, & Limstrom, 2008; Mintz-Hittner & Fernandez, 2000;
Park, Hwang, & Ahn, 2004), or the interdependence of the two
(Oliver et al., 1986) for successful treatment. In accordance with
the MOTAS/ROTAS studies (Stewart et al., 2004b, 2007a, 2007b)
and a meta-analysis of the Amblyopia Treatment Studies (ATS,
Holmes et al., 2011), we found decreasing susceptibility of the
visual system with age to the enforced use of the amblyopic eye.
The studies of Stewart et al. (2004b, 2007a, 2007b) covered age
groups younger than ours (with some overlap, showing good
agreement of results), and collected objective dose rate data allow-
ing the calculation of dose–response relationship of treatment.
Although without treatment monitoring, the ATS described a non-
linear relationship between age and improvement, with a differ-
ence in responsiveness to treatment between patients younger
and older than 7 years of age. Our study conﬁrmed the nonlinear
trend as well as signiﬁcant differences between these age groups,
adding novel data on the efﬁciency of treatment calculated on
the basis of objective ODM recordings.
4.3. Considerations about mechanisms
In recent decades, a number of beliefs concerning the time span
of maturation (later than assumed) and residual adaptability (more
than suspected) of the visual system has had to be revised. Acuity
development (especially crowded acuity) seems to continue to
some extent until even after the age of 11 years (Haase, 2003;
Jeon et al., 2010). Bavelier et al. (2010) and Baroncelli, Maffei,
and Sale (2011) have given comprehensive overviews of the cur-
rent considerations and open questions about the changes govern-
ing development and late plasticity. It is still unclear to what
extent later improvement is based on unmasking of previously
established, but inhibited circuitry via alteration of the excit-
atory/inhibitory balance, or on the development of new connec-
tions after removal of structural ‘‘brakes’’, and how this changes
with age. The binocular training applied by Hess, Mansouri, and
Thompson (2011) assumes a structurally intact binocular system
in amblyopia which needs reduction of inhibitory inﬂuence.
Our study adds to the sparsely available data about susceptibility
to occlusion treatment during the period of transition from child-
hood to adolescence. Unfortunately the clinical history of amblyo-
pes is usually not clear enough to allow assumptions about the
period of normal development after which amblyogenic factors or
amblyopia occurred. Our preliminary prospective data on the devel-
opment of the depth of interocular suppression during occlusion
treatment in amblyopes of this age span suggest that suppression
and acuity do not change in parallel (Fronius et al., 2013), making
a simple relationship (enhanced acuity due to reduced suppression)
unlikely. Reﬁnedmethods for quantifying the depth of suppression,
applicable also in younger children (e.g. Narasimhan, Harrison, &
Giaschi, 2012), may enhance understanding of these phenomena.
4.4. Future prospects
After the procedure has been established, age dependent sus-
ceptibility of further visual functions with different critical periods
(Daw, 1998) may be analyzed in conjunction with quantiﬁed inten-
sity of occlusion. Correlations between them may elucidate mech-
anisms of plasticity of various structures in the visual system. Our
data may gain additional importance in the context of variousattempts to inﬂuence amblyopia with alternative approaches such
as perceptual learning (Astle, Webb, & McGraw, 2011; Levi & Li,
2009; Polat, Ma-Naim, & Spierer, 2009), playing video games (Li
et al., 2011), various types of binocular training (Hess, Mansouri,
& Thompson, 2011; Knox et al., 2012), as well as acupuncture
(Zhao et al., 2010), pharmacological enhancement (Campos &
Fresina, 2006; Maya Vetencourt et al., 2008), and transcranial mag-
netic (rTMS, Clavagnier, Thompson, & Hess, 2013; Thompson et al.,
2008) or current stimulation (Spiegel et al., 2013a, 2013b), many of
which are hardly applicable in young children. Our acuity gain,
dose–response and efﬁciency data may serve as reference for the
age dependent effort (e.g. hours of training) necessary to achieve
a corresponding effect like with patching.
Findings from studies demonstrating effects of late treatment for
amblyopia have already had political implications: in Germany the
implementation of pre-school screening for amblyopia/amblyogen-
ic factors by ophthalmologists and orthoptists was turned down
with the argument that currently, based on available evidence from
studies, it could not be ruled out that amblyopia treatment was
equally effective in childhood and in adolescence. In our study treat-
ment efﬁciency declined signiﬁcantly with age, suggesting that for
the same treatment effect (e.g. acuity gain of 2 lines after 4 months),
patients aged between5 and 7 years had to patch on average around
200 h, those over 7 years more than 400 h, which implies a consid-
erable difference in the feasibility of treatment and associated
reduction of quality of life (Pieh et al., 2009). Better availability of
ODMs in the future will allow recording of longer periods in larger
groups of patients, elucidating more comprehensively effective
duration and factors inﬂuencing treatment success.
4.5. Conclusion
Electronically recorded occlusion allowed insight into age-
dependent efﬁciency of patching treatment for amblyopia, in pre-
viously untreated patients between 5 and 16 years of age. Efﬁ-
ciency is suggested to extend knowledge about declining
functional plasticity of the human visual system, and to supply a
basis for comparison of effects of patching vs. emerging alternative
approaches for amblyopia treatment.
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